New approaches are being developed for the manufacturing of therapeutic oligonucleotides, with a focus on improving production methods. These innovations include the use of enzymatic platforms, chemoenzymatic ligation, and precision chemistry to increase efficiency and scalability. The development of these new methods may lead to less expensive and higher production capabilities for oligonucleotide therapy firms.